Literature DB >> 24928784

Implications of targeted versus universal admission screening for meticillin-resistant Staphylococcus aureus carriage in a London hospital.

J A Otter1, Olga Tosas-Auguet2, M T Herdman3, B Williams3, D Tucker3, J D Edgeworth2, G L French2.   

Abstract

Universal admission screening for meticillin-resistant Staphylococcus aureus (MRSA) has been performed in England since 2010. We evaluated the predictive performance of a regression model derived from the first year of universal screening for detecting MRSA at hospital admission. If we had used our previous targeted screening policy, 75% fewer patients (21,699 per year) would have been screened. However, this would have identified only ~55% of all MRSA carriers, 65% of healthcare-associated MRSA strains, and 40% of community-associated strains. Failing to identify ~45% of patients (262 per year) carrying MRSA at hospital admission may have implications for MRSA control.
Copyright © 2014 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Admission; Carriage; Colonization; Meticillin-resistant Staphylococcus aureus; Prevalence; Screening

Mesh:

Year:  2014        PMID: 24928784     DOI: 10.1016/j.jhin.2014.04.005

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  2 in total

1.  Evaluation of the Hologic Panther Fusion MRSA Assay for the detection of MRSA in ESwab specimens obtained from nose, throat, and perineum.

Authors:  Mette Damkjær Bartels; Danah Knudsen; Henrik Westh; Kristian Schønning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-05-11       Impact factor: 3.267

2.  Cost Analysis of Universal Screening vs. Risk Factor-Based Screening for Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Virginia R Roth; Tara Longpre; Doug Coyle; Kathryn N Suh; Monica Taljaard; Katherine A Muldoon; Karamchand Ramotar; Alan Forster
Journal:  PLoS One       Date:  2016-07-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.